CR20140408A - Formas cristalinas de cloruro de hidrógeno de 1-(3-terc-butil-1-p-totil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi) bencil)urea - Google Patents

Formas cristalinas de cloruro de hidrógeno de 1-(3-terc-butil-1-p-totil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi) bencil)urea

Info

Publication number
CR20140408A
CR20140408A CR20140408A CR20140408A CR20140408A CR 20140408 A CR20140408 A CR 20140408A CR 20140408 A CR20140408 A CR 20140408A CR 20140408 A CR20140408 A CR 20140408A CR 20140408 A CR20140408 A CR 20140408A
Authority
CR
Costa Rica
Prior art keywords
indazol
fluoro
hydroxyethyl
urea
hydrogen chloride
Prior art date
Application number
CR20140408A
Other languages
English (en)
Inventor
Alisha B Arrigo
Donald T Corson
Coralee G Mannila
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47891993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140408(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CR20140408A publication Critical patent/CR20140408A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56Benzopyrazoles; Hydrogenated benzopyrazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

En la presente se proporciona una sal de cloruro de hidrógeno de 1-(3-terc-butil-1-p-tolil-1H-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1H-indazol-5-iloxi)bencil)urea, formas 5 cristalinas de clorhidrato de 1-(3-terc-butil-1-p-tolil-1H-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1H-indazol-5-iloxi)bencil)urea,
CR20140408A 2012-03-01 2014-09-03 Formas cristalinas de cloruro de hidrógeno de 1-(3-terc-butil-1-p-totil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi) bencil)urea CR20140408A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605572P 2012-03-01 2012-03-01
PCT/US2013/027979 WO2013130573A1 (en) 2012-03-01 2013-02-27 Crystalline forms of 1- (3 -tert-butyl- 1 - p-tolyl- 1h- pyrazol- 5 -yl) -3- (5-fluoro-2- (1- ( 2 - hydroxyethyl) - indazol- 5 -yloxy) benzyl) urea hydrochloride

Publications (1)

Publication Number Publication Date
CR20140408A true CR20140408A (es) 2014-10-14

Family

ID=47891993

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140408A CR20140408A (es) 2012-03-01 2014-09-03 Formas cristalinas de cloruro de hidrógeno de 1-(3-terc-butil-1-p-totil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi) bencil)urea

Country Status (28)

Country Link
US (1) US9278936B2 (es)
EP (2) EP4101844A1 (es)
JP (2) JP6177809B2 (es)
KR (2) KR102298597B1 (es)
CN (1) CN104245677B (es)
AR (1) AR090209A1 (es)
AU (1) AU2013226163B2 (es)
CA (1) CA2865808C (es)
CL (1) CL2014002296A1 (es)
CO (1) CO7071134A2 (es)
CR (1) CR20140408A (es)
DK (1) DK2819998T3 (es)
ES (1) ES2919923T3 (es)
HK (1) HK1204475A1 (es)
IL (1) IL234192B (es)
MX (1) MX355734B (es)
MY (1) MY183153A (es)
NZ (1) NZ630033A (es)
PH (1) PH12014501834A1 (es)
PL (1) PL2819998T3 (es)
PT (1) PT2819998T (es)
RU (1) RU2627702C2 (es)
SG (1) SG11201405357SA (es)
SI (1) SI2819998T1 (es)
TW (1) TWI610673B (es)
UA (1) UA113302C2 (es)
UY (1) UY34647A (es)
WO (1) WO2013130573A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3157928T (pt) 2014-06-20 2019-05-30 Constellation Pharmaceuticals Inc Formas cristalinas de 2-((4s)-6-(4-clorofenil)-1-metil-4h-benzo[c] isoxazolo[4,5-e]azepin-4-il)acetamida
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
AU2018346712B2 (en) 2017-10-05 2021-04-01 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2023084459A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating sars-cov-2
CN117198527B (zh) * 2023-08-24 2024-02-23 北京大学人民医院 一种亲缘造血干细胞移植术后的风险评估系统及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596306B1 (en) 2000-07-07 2003-07-22 David Ho Sue San Ho Drug delivery system:formulation for fat-soluble drugs
JP2002249426A (ja) * 2000-12-22 2002-09-06 Takeda Chem Ind Ltd 経口医薬組成物
FR2818905A1 (fr) 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
BR0214679A (pt) * 2001-12-03 2004-12-14 Novacea Inc Composições farmacêuticas compreendendo compostos a base de vitamina d ativa
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2004078116A2 (en) * 2003-03-03 2004-09-16 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1670787B1 (en) * 2003-09-11 2012-05-30 iTherX Pharma, Inc. Cytokine inhibitors
NZ570846A (en) * 2006-01-31 2011-08-26 Array Biopharma Inc Kinase inhibitors and methods of use thereof

Also Published As

Publication number Publication date
CA2865808A1 (en) 2013-09-06
US20150030673A1 (en) 2015-01-29
WO2013130573A1 (en) 2013-09-06
UA113302C2 (xx) 2017-01-10
CL2014002296A1 (es) 2014-11-07
JP2017128591A (ja) 2017-07-27
RU2627702C2 (ru) 2017-08-10
NZ630033A (en) 2016-09-30
CO7071134A2 (es) 2014-09-30
RU2014139607A (ru) 2016-04-20
JP6177809B2 (ja) 2017-08-09
SG11201405357SA (en) 2014-10-30
TW201336494A (zh) 2013-09-16
PL2819998T3 (pl) 2022-06-27
UY34647A (es) 2014-09-30
PT2819998T (pt) 2022-05-05
PH12014501834B1 (en) 2014-11-10
US9278936B2 (en) 2016-03-08
DK2819998T3 (da) 2022-04-19
EP2819998B1 (en) 2022-04-06
MX355734B (es) 2018-04-27
ES2919923T3 (es) 2022-07-29
TWI610673B (zh) 2018-01-11
CA2865808C (en) 2020-07-14
EP2819998A1 (en) 2015-01-07
AU2013226163B2 (en) 2017-06-08
IL234192A0 (en) 2014-11-02
PH12014501834A1 (en) 2014-11-10
EP4101844A1 (en) 2022-12-14
CN104245677B (zh) 2017-05-10
AU2013226163A1 (en) 2014-09-25
MY183153A (en) 2021-02-16
IL234192B (en) 2019-11-28
KR102477065B1 (ko) 2022-12-13
KR102298597B1 (ko) 2021-09-06
HK1204475A1 (en) 2015-11-20
MX2014010538A (es) 2015-03-09
SI2819998T1 (sl) 2022-07-29
JP2015508820A (ja) 2015-03-23
KR20210113410A (ko) 2021-09-15
CN104245677A (zh) 2014-12-24
KR20140138233A (ko) 2014-12-03
AR090209A1 (es) 2014-10-29

Similar Documents

Publication Publication Date Title
CR20140408A (es) Formas cristalinas de cloruro de hidrógeno de 1-(3-terc-butil-1-p-totil-1h-pirazol-5-il)-3-(5-fluoro-2-(1-(2-hidroxietil)-1h-indazol-5-iloxi) bencil)urea
IL242286A0 (en) Modified 2)-n-methoxy-5-nitrophenyl)pyrimidine-2-amine compounds and their salts
IL256141B (en) Hydrogen passivation of non-linear optical crystals
EP2754032A4 (en) CONTEXT-WANTED TRANSFORMATION DATA SOURCE MANAGEMENT
UY34039A (es) Compuestos fungicidas
EP2732133A4 (en) ACOUSTICAL DIAGRAPHY TOOL DURING DRILLING EQUIPPED WITH ACTIVE SOURCE ORIENTATION CONTROL
PL2890613T3 (pl) Zasilane baterią narzędzie napinające do taśmy
UY34158A (es) Composicion herbicida
LTPA2020526I1 (lt) 2-Acilaminotiazolo junginio kristalai
AR098592A1 (es) Formas cristalinas de 1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azulenos
BR112013023480A2 (pt) composto heterocíclico saturado contendo nitrogênio
UY34032A (es) Nuevos inhibidores de quinasa
CR20120206S (es) Batería
CO6862150A2 (es) Cristal de compuesto heterocíclico fusionado
CY1120784T1 (el) Νεα κρυσταλλικη μορφη
TR201111589A2 (tr) Tiotropyum bromür susuz kristal formu.
DE102011075568A8 (de) Membranspannfutter und Werkzeugmaschine
UA65357U (ru) Применение полипропиленовой клейкой ленты в качестве смазочно-охлаждающего технологического средства
ES1076437Y (es) Portagafas
UA64833U (en) Light-emitting-diode module